Inferra AIResearch Tools

Inferra AI / Company / ARGX

Argenx

ARGX · Health Care

Last earnings Oct 22, 2026

Important announcements

argenx to Present Phase 3 ALKIVIA Results inOct 19, 2026argenx Announces Positive Topline Results fromOct 8, 2026argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's DiseaseOct 8, 2026

Key results

EPSytd

$12.41

On a per weighted average share basis, the basic earnings per share was $12.41 for the nine months ended September 30, 2025 compared to $0.99 for the nine months ended September 30, 2024.

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

AI analysis

Q3 2025 · reported Oct 30, 2025

Based on: Earnings release (6-K exhibit) + Q3 2025 deck + parent 6-K — transcript not held

EPS · Year to date
$12.41
EX-99 · Oct 30, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
EPS$12.41——

EX-99 · Oct 30, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Argenx Q3 2025 — On a per weighted average share basis, the basic earnings per share was $12.41 for the nine months ended September 30, 2025 compared to $0.99 for the nine months ended September 30, 2024.

Based on: Earnings release (6-K exhibit) + Q3 2025 deck + parent 6-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

Vision 2030 Strategic Priorities argenx is advancing its Vision 2030 strategic priorities, anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030.

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

The research and development expenses mainly related to Advancing efgartigimod across multiple severe autoimmune indications, supporting ongoing registrational and expansion studies Progressing empasiprubart into multiple indications namely in MMN, DGF and CIDP Executing studies for ARGX-119 in rare neuromuscular diseases, including a registrational study in CMS and proof-of-concept studies in ALS and SMA and Early-stage discovery and preclinical programs to sustain long-term pipeline growth.

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

Manufacturing to support future VYVGART and pipeline growth 20 Active IIP Programs Investing in Our Future Collaborators 4 New Molecules in Phase 1 by year end 7 8 *Net sales growth % excludes the impact of fx.

SEC original ↗Argenx — Presentation / slide deck (6-K exhibit)EX-99Oct 30, 2025

Risks & headwinds

Topline results from registrational EMPASSION study (MMN) expected in second half of 2026 Registrational EMVIGORATE and EMNERGIZE studies ongoing (CIDP) Topline data from Phase 2 VARVARA study (DGF) expected around year-end 2025 Stopped development of empasiprubart in DM due to operational challenges with enrollment of proof-of-concept EMPACIFIC study ARGX-119 Development ARGX-119, a first-in-class agonist antibody that targets muscle-specific kinase (MuSK), is now a registrational asset following positive proof-of-concept data in congenital myasthenic syndromes (CMS).

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance.

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

A further list and description of these risks, uncertainties and other risks can be found in argenx s U.

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

SEC original ↗Argenx — Earnings release (6-K exhibit)EX-99Oct 30, 2025

Documents

Earnings deck slides

1 deck with slide view

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Argenx — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health CareJohnson & Johnson (JNJ) Health Care

Filings

93 documents

Earnings releases

31 documents

Presentations

14 documents

Transcripts

0 documents

No transcripts for Argenx are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Argenx by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.